FDA Issues Warning to New Jersey Developer for Marketing Unapproved Stem Cell Product – Rare Disease Report
The Pharma LetterFDA Issues Warning to New Jersey Developer for Marketing Unapproved Stem Cell ProductRare Disease Report“We see great promise from the field of cell based regenerative medicine, but there are also novel risks,” continued Gottlieb. “Our… Continue reading
